CD226 and pancreatic neoplasm: Additionally, recent studies demonstrated that the CD155/TIGIT axis is a key driver of immune evasion in pancreas cancer (18), and that both PD-1 and TIGIT signaling impairs CD226 co-stimulation (17) which is required for restoring antitumor immunity.